Summary Box: FDA expands approval of J&J drug
WASHINGTON (AP) - FDA OK: The Food and Drug Administration on Monday approved the drug Zytiga for a new group of prostate cancer patients who have not yet received chemotherapy.
FAMILIAR FACE: The FDA previously approved the pill from Johnson & Johnson for men with prostate cancer who have already taken the chemotherapy drug docetaxel.
HALTING HORMONES: Zytiga works be decreasing the male hormone testosterone, which spurs growth of prostate tumors.
(Copyright 2012 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.)